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Abstract The use of whole genome amplification (WGA) and
whole transcriptome amplification (WTA) techniques enables
the enrichment of DNA and RNA from very small amounts of
tissue. Here, we tested the suitability of WGA and WTA for
tumor tissue biobanking. DNA and RNA from 13 standardized
and seven non-standardized frozen and 12 formalin-fixed,
paraffin-embedded (FFPE) clear cell renal cell carcinoma
specimens (>9 years old) served to test the robustness of the
WGA andWTA products by reidentifying von Hippel–Lindau
(VHL) gene mutations known to exist in these samples. The
enrichment of DNA and RNA from frozen tissue was up to
1,291-fold and 423-fold, respectively. The sizes and yields (10-
to 73-fold) of the amplified DNA obtained from the 12 FFPE
samples were generally lower. The quality of the RNA from the
FFPE samples was too low to reliably perform WTA. Our
results demonstrate that frozen tumor tissue is very suitable
for WGA andWTA. All 20 VHLmutations were verified with
WGA. Notably, we were able to show that 18 of the 20 (90 %)
VHLmutations are also transcribed. In FFPE tumor tissue, 8 of
12 cases (67 %) showed the expected mutations after the first
WGA. Accurate WTAwith FFPE material is sophisticated and
strongly depends on the modification and degradation status of
the fixed tissue. We conclude that for sustainable tissue bio-
banking, the use of WGA and WTA is a unique opportunity to
provide researchers with sufficient amounts of nucleic acids,
preferably from limited frozen tissue material.
Keywords WGA .WTA . Tissue biobank . VHL gene .
Mutation analysis
Introduction
Tumor tissue biobanks represent an ideal platform for trans-
lational research. Large tumor tissue collections exist in
pathology institutes at universities in which thousands of
tissue samples are stored. In general, tumor tissue samples
are formalin-fixed and paraffin-embedded (FFPE). The vol-
ume of archived tissue samples is limited by the size of the
paraffin block and varies between a few cubic millimeter
(fine needle biopsies) and 1–2 cm3.
Due to formalin fixation, the molecular structures in
FFPE material become modified, degraded, and cross-
linked [1] and are of limited value, particularly when high-
throughput technologies, such as DNA microarrays, deep
sequencing, or mass spectrometry, are to be applied. As a
result, frozen tumor tissue samples not required for diagnostic
purposes are routinely collected in parallel in many pathology
institutes.
According to the recommendations of the TuBAFrost
consortium [2], approximately 0.5 cm3 is the ideal size for
collecting frozen tumor tissue samples in a tumor tissue
biobank. This is also in line with our standardized operating
procedure for freezing and processing tumor tissues which
was established at the Central Tissue Biobank at the Uni-
versity Hospital of Zurich [3].
Depending on the organ and the surgical resection spec-
imen that a tumor originated from, residual tissue fragments
available for the biobank may be very small. Furthermore, it
is expected that ongoing optimization of surgical dissection
techniques and cancer screening tests will lead to a further
increase of micro-biopsy samples in the biobanks. Subse-
quently, although the demand for tumor tissue in the cancer
research community is rising, the tissue material available
for research projects will become more and more limited in
the near future. In addition, once tumor samples have been
depleted, these samples are no longer available for further
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studies. As a consequence, biobank managers are forced to
look for suitable strategies to help prevent the wasting of
valuable tumor tissue material. The amplification of whole
genomes and transcriptomes of tumor tissue samples may be
such an approach.
Several companies offer commercially available kits
which allow the amplification of the human genome and
transcriptome up to over 1,000-fold [4–6]. In this study, we
evaluated the suitability of a whole genome amplification
(WGA) and a whole transcriptome amplification (WTA) kit
for tumor tissue biobanking using tissue from FFPE and
frozen clear cell renal cell carcinoma (ccRCC) specimens.
The GenomePlex® WGA2 kit (Sigma-Aldrich) is based on
the random fragmentation of genomic DNA and conversion
of the resulting small fragments to PCR-amplifiable DNA
molecules flanked by universal priming sites. In the whole
transcriptome amplification kit (WTA2, Sigma-Aldrich),
RNA undergoes a single-step conversion into cDNA frag-
ments flanked by universal priming sites followed by a
subsequent PCR amplification of the resulting cDNA library
using universal oligonucleotide primers. The accuracy and
robustness of the WGA and WTA products were tested
using RCC samples with known von Hippel–Lindau (VHL)
mutations [7].
Materials and methods
Tissue and nucleic acid extraction
Twenty frozen and 12 FFPE unrelated ccRCC specimens
with known VHL mutations [7] were selected for this study
to test whether WGA and WTA are applicable to tissues that
were treated differently and of a different age. Thirteen of
the 20 samples were frozen according to a standardized
procedure [3] which was established at our institute in
2006 and were expected to serve as “positive controls”.
The remaining seven tissues were collected before 2006
using non-standardized protocols. The 12 FFPE ccRCC
specimens were between 9 and 19 years of age. The VHL
mutations are listed in Tables 1 and 2. Hematoxylin and
eosin-stained (HE) sections were reviewed by one patholo-
gist (H.M.). All tumor samples contained at least 70 %
tumor cells. Magnified HE sections of three tumors are
shown in Fig. 1. DNA and RNA were isolated from one
and five 20 μm frozen sections, respectively, using the
DNeasy Blood and Tissue and the RNeasyMini Kits (Qiagen,
Hilden, Germany), respectively. DNA and RNA from FFPE
tissue were isolated from three punched tissue cylinders
(diameter 0.6 mm) using the EZ1 DNA Tissue kit (Qiagen)
and an RNA extraction protocol [8], respectively. The concen-
trations of the obtained nucleic acids were measured using the
Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA).
Whole genome and transcriptome amplification
The GenomePlex® WGA2 and WTA2 tissue kits (Sigma-
Aldrich, St. Louis, MO, USA) were used to amplify the
genomes and transcriptomes of both frozen and FFPE tissue.
We used between 8 and 38 ng of DNA and RNA from
frozen tissue, and 100 ng of DNA from FFPE material as
input for the WGA and the WTA, respectively. The quality
of the amplified DNA was analyzed on 1.5 % agarose gels.
The amplified products were purified using the MinElute
PCR Purification Kit (Qiagen), and the concentrations were
measured using the Nanodrop.
VHL mutation analysis
PCR of the three VHL exons in the amplified genomes was
performed as previously described [9]. One hundred nano-
grams of amplified DNA was used as template.
Using the Primer3 online program, new primers were
designed to analyze the VHL mutations in the amplified
transcriptomes. One primer pair (forward: 5′-gagtacggccct
gaagaaga-3′; reverse: 5′-ggcacaaataattcagtttggtt-3′; 350 bp)
spanned exons 1 and 2. The second primer pair (forward: 5′-
acacgatgggcttctggtta-3′; reverse: 5′-tcaatctcccatccgttgat-3′;
271 bp) spanned exons 2 and 3. One hundred nanograms
of amplified cDNA was used as template.
Sequencing of the PCR products was performed by the
dideoxy chain-termination method using the BigDye® Ter-
minator v1.1 Cycle Sequencing kit (Applied Biosystems).
Forward and reverse primers used for the PCR were also
used for sequencing. Cycle sequencing products were ana-
lyzed using the AbiPrism 3100 Genetic analyzer (Applied
Biosystems).
A second PCR was performed if no amplified product or
no VHL mutation was obtained. If the result was not in
accordance with the expected result, the original DNA or
RNA was subjected to a second or third WGA or WTA,
respectively. The products underwent VHL-PCR and DNA
sequencing as described above.
Results
Whole genome amplification
Between 8 and 35 ng of DNA was used as template for the
whole genome amplification of frozen ccRCC tissue. The
sizes of the resulting PCR products ranged between 100 and
1,000 bp (Fig. 2a). A DNAyield between 2.98 and 17.36 μg
of DNA was obtained. Seventeen samples had more than
10 μg of DNA which is equivalent to a 300- to 1,291-fold
enrichment. There were no significant differences in the
amplified DNA sizes and the yields between tissue samples
572 Virchows Arch (2012) 461:571–580
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Table 2 WGA results with FFPE ccRCC tissue
Year of
sample
VHL mutation Starting amount
DNA (ng)
DNA yield
(µg)
OD 260/280 Fold
enrichment
Result
1993 c.491_494delAGGT/p.Gln164fs 100 2.89 1.8 29 Correct (1st WGA)
1994 c.257C > A/p.Pro86His 100 1.26 2.01 13 Correct (1st WGA)
1995 c.389T > A/p.Val130Asp 100 1.1 1.71 11 Different mutation (1st WGA)
No mutation (2nd WGA)
1995 c.472C > G/p.Leu158Val 100 3.19 1.89 32 Correct (1st WGA)
1995 c.374_380del/p.His125fs 100 1.93 1.83 19 Correct+additional mutation (1st WGA)
Correct (2nd WGA)
1997 c.234T > A/p.Asn78Lys 100 1.04 1.68 10 Correct (1st WGA)
2000 c.468_470delTAC/p.Tyr156 100 6.01 1.85 60 No mutation (1st WGA)
Correct (2nd WGA)
2000 c.409delG/p.Val137fs 100 4.5 1.86 45 Correct (1st WGA)
2001 c.323insC/p.Arg108fs 100 4.26 1.87 43 Correct (1st WGA)
2002 c.234T > G/p.Asn78Lys 100 3.5 1.78 35 Correct (1st WGA)
2002 c.452T > C/p.Ile151Thr 100 7.26 1.88 73 Correct + additional mutation (1st WGA)
Correct (2nd WGA)
2003 c.264G > T/p.Trp88Cys 100 2.2 1.78 22 Correct (1st WGA)
A
B
Fig. 1 HE sections of two
homogenous ccRCC cases with
strongly dominating VHL
wildtype sequences. Tumors
with VHL mutations
c.458T>C/p.Leu153Pro and
c.564-565GG>AT/p.Leu-
Glu188-189LeuX, respectively.
Details are shown in Table 1
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collected under standardized and non-standardized condi-
tions. The detailed results are shown in Table 1.
In contrast to the frozen tissue samples, the sizes and
yields of the genomic DNA amplification products obtained
from the 12 FFPE ccRCC samples varied significantly
among each other and were generally lower (Fig. 2b). As
recommended by the supplier, 100 ng of DNA from each of
the ccRCC samples was used as input for the whole genome
amplification. The DNA yields were between 1.04 and
7.26 μg, which is equivalent to a 10- to 73-fold enrichment.
Details are listed in Table 2.
Whole transcriptome amplification
Fifteen to 38 ng of RNA, extracted from the same 20 frozen
ccRCC samples, was used for the whole transcriptome ampli-
fication. The quality of the amplified cDNAwas not analyzed.
Between 4.2 and 14.9 μg of amplified cDNA was obtained
after the WTA, which is a 202- to 423-fold enrichment. The
sizes and yields of amplified cDNA obtained from standard-
ized and non-standardized tissue sets were comparable. The
results are shown in Table 1.
We also intended to perform WTA with the same 12
FFPE ccRCC samples used for WGA. However, as we were
not able to amplify sufficient amounts of the two PCR
products from the original RNA extracts (Fig. 3), particu-
larly the 350 bp fragment which spans the VHL exons 1 and
2, we decided to omit this analysis.
VHL mutation analysis of WGA products
The WGA products served as DNA templates for VHL
exon-specific PCRs. For each sample, only the primer pair
covering the known mutated exon was used. Fourteen of the
20 (70 %) amplified DNA samples showed the correct
mutation after the first WGA. The WGA of six samples
using the original DNA preparation from tissues was repeat-
ed because the expected VHLmutation was not visible in the
DNA sequence. However, it is important to note that in the
original DNA of these six ccRCC cases, the VHL wild-type
sequence was strongly dominating and the mutated se-
quence was underrepresented. The VHL mutations of two
tumors are illustrated in Figs. 4 and 5. The results of the
WGA are shown in Table 1.
The genomes of all of the 12 ccRCC FFPE samples were
successfully amplified. After the first WGA, eight (67 %) of
these showed the expected mutations. Two cases showed the
expected mutations and an additional VHL mutation. Of the
last two cases, one had no mutation and the other had a
different VHL mutation. After repeating the WGA with the
original DNA samples of the four tumors that showed dis-
crepant results, three had the correct mutation and one had no
mutation. The results are shown in Table 2. An example of a
VHL mutation identified in the original DNA and after WGA
of one ccRCC is shown in Fig. 4a and b, respectively.
VHL mutation analysis of WTA products
To see whether a VHL gene affected with a mutation is also
transcribed in ccRCC, the WTA products of the 20 frozen
ccRCC were subjected to a PCR which specifically ampli-
fies VHL expressed alleles. Surprisingly, 13 of 20 (65 %)
VHL mutations were confirmed as transcribed after the first
WTA and five (25 %) after the second PCR or the second
WTA. Six of the 20 analyzed ccRCCs had frameshift muta-
tions which probably lead to a loss of function of the VHL
protein (pVHL). The frameshift mutations identified in the
genomic DNA of the two ccRCC samples could not be
verified in the corresponding WTA products. The tran-
scribed VHL mutations of two tumors are shown in Figs. 4c
and 5c. The results are listed in Table 1.
Discussion
In this study, we demonstrate that WGA and WTA are well
suited to sufficiently and accurately enrich DNA and RNA
from frozen tumor tissue. The whole amplification of
genomes and transcriptomes of nucleic acids extracted from
FFPE tumor tissues, however, has limitations. Below, we
address some critical points which are of general importance
if these methods are used to amplify DNA and RNA from
B
M   T3 T4 T5 T6 T7
A
600 bp
T1 T2
M C T1 T2 T3 T4 T5
100 bp
100 bp
600 bp
Fig. 2 A 1.5 % agarose gel with WGA products of DNA isolated from
five frozen ccRCCs (a) and of DNA isolated from seven FFPE ccRCCs
(b). M, 100 bp DNA ladder; C, negative control (no DNA template);
T1, tumor 1, etc
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cancer tissue. For tumor tissue biobanking, these technolo-
gies may help to permanently provide sufficient amounts of
high quality nucleic acids from limited and valuable tumor
tissue material for research purposes.
Mutated VHL alleles are commonly transcribed in ccRCC
It is widely accepted that in ccRCC, VHL inactivation fol-
lows the two-hit mechanism with loss of the chromosomal
3p arm and a mutation of VHL in the remaining allele.
Recently, we showed that VHL mutations may exert differ-
ent impacts on pVHL’s functionality [7] provided that the
mutated gene is expressed. Several data exist about pVHL
expression in ccRCC [10–15], but the expression status of
mutated VHL alleles has not been reported to date. Here, we
were able to demonstrate that most of the VHL mutated
alleles are transcribed, regardless of their mutation type. It
is, consequently, conceivable that the location and the type
Exon 1 Exon 2
Exon 1 Intron 1
Exon 1 Intron 1
B
A
C
Fig. 4 VHL mutation c.300_308del/p.Thr100_Pro103delinsThr in the original DNA of one ccRCC patient (a), after WGA (b), and after WTA (c).
The mutation site is denoted by an arrow. The boundaries between exon 1/intron 1 and exon 1/exon 2 are indicated
M L1 L2 P1 P2 pK  pC  nC L1 L2 P1 P2 pK pC  nC
500 bp
100 bp
Fig. 3 Reverse transcription-PCR analysis of the 350 bp (exon 1/2)
and the 271 bp (exon 2/3) VHL fragments. M, 100 bp DNA ladder; L1
and L2, FFPE normal liver; P1 and P2, FFPE normal prostate; pK,
WTA amplified cDNA control from frozen normal kidney; pC, plas-
mid containing the whole VHL coding sequence (positive control); nC,
negative control (no cDNA template)
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of a VHL mutation may have dramatic effects on the multi-
adaptor functions of pVHL [16] as well as on tumor behavior
and response to targeted therapies. Although evidence of
mutant pVHL expression in ccRCC has not been reported,
previous immunohistochemistry data indicate the presence of
pVHL in the majority of ccRCC [10–15].
WGA of DNA extracted from frozen tumor tissue
The DNA obtained after WGA was up to 1,300-fold
enriched which is in the range described by the supplier.
After the first WGA, the expected VHL mutation was pres-
ent in 14 of 20 samples but absent in six samples. After
repeating the WGA from original tissue DNA, all six cases
showed the correct VHL mutation. In all 20 samples, even in
the six ccRCC cases in which the VHL mutated sequences
were significantly underrepresented, the sizes of the result-
ing sequence peaks of both the wild-type and the mutated
VHL sequences obtained after WGA were comparable with
those of the original, unamplified DNA (see Fig. 4). As the
tumor specimen used for the WGA and sequence analyses
consisted of more than 70 % tumor cells, we believe that the
observed underrepresention of VHL mutations in the six
ccRCC is a matter of genetic heterogeneity of the tumor
cells. Intratumoral heterogeneity was described in a former
study in which VHL deletions were analyzed [17]. We
conclude that in tumor types that are more heterogeneous
than RCC, underrepresented gene sequence alterations may
frequently be missed after WGA if whole sections are used
for DNA extraction. To minimize this problem, DNA should
be extracted from micro-dissected or punched tumor areas
rather than from whole tumor sections.
WGA of DNA extracted from FFPE tumor tissue
Although the starting amount of DNA extracted from FFPE
ccRCC tissue was 100 ng, the enrichment of DNA was
about tenfold lower when compared to WGA with DNA
extracted from frozen tumor tissue. WGA with 10 ng of
DNA resulted in significantly less amplification product
(data not shown). Two-thirds of the samples had the correct
mutation after the first WGA. Discrepant results were
obtained from the four remaining cases that had either
different, additional, or no VHL mutations. After a second,
separate WGA, three of these cases showed the correct
mutation and only one case (with a different mutation after
the first WGA) had no mutation. It is known that the
frequency of damaged bases can vary considerably due to
the fixation time and the modifying effects of formalin on
DNA in tissue [18, 19]. Therefore, the results obtained from
a mutation analysis should be interpreted with care. In a
previous comprehensive VHL mutation study, we could not
validate the results from approximately 10 % of the
formalin-fixed ccRCC samples [7]. At least two indepen-
dent rounds of PCR and sequencing were performed to
distinguish between real and artificial mutations.
A previous study showed that FFPE tissue is less accurate
than frozen material for determining mutations in tumors
[20]. If WGA is to be performed with DNA from FFPE
tumor material, we suggest that two separate parallel WGA
A
Exon 3 Intron 2
B
Exon 3 Intron 2
Exon 3 Exon 2
C
Fig. 5 VHL mutation c.484T>C/p.Cys162Arg in the original DNA of
one ccRCC patient (a), after WGA (b), and after WTA (c). The sequence
is shown in reverse and the mutation site is denoted by an arrow. The
boundaries between exon 3/intron 2 and exon 3/exon 2 are indicated
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rounds using DNA from original tissue are carried out to
select bad from good quality tissue specimens. As a quality
control of the whole genome amplified DNA, any exonic
sequence can be PCR-amplified and sequenced. If the two
obtained sequences are well analyzable and identical, then
the integrity of the WGA DNA is given. In case of a
discrepancy between the sequences, a third WGA, PCR,
and sequencing analysis should be included and compared
with the first two sequences. If this third WGA sequence
corresponds to one of the others, these two may be used for
further molecular analyses. If, however, three different
results are obtained, this tissue sample should not be con-
sidered for further analyses. The proposed strategy for test-
ing the quality of WGA products is schematically illustrated
in Fig. 6.
To further minimize PCR artifacts, the use of non-cross-
linking fixatives may be an alternative to buffered formalin as
the quality of the nucleic acids seems to be similar to those
derived from frozen tissue [21, 22]. A further optionmay be to
treat DNA isolated from FFPE tissue with uracil-DNA glyco-
sylase to reduce uracil lesions which are the major cause of
sequence artifacts [23].
WTA of RNA extracted from frozen tumor tissue
The enrichment of amplified cDNA varied only between
200- and 400-fold, indicating a uniform WTA of all 20
RNA samples. With the exception of two ccRCC samples,
which had VHL frameshift mutations in the original DNA,
the expected VHL mutations were found to be transcribed in
FFPE DNA
WGA 1 WGA 2
PCR and
sequencing 1
PCR and
sequencing 2
3 possible outcomes
A
Both sequences are 
good, then ideal 
situation
One good (1) and one 
bad sequence (2), then 
repeat WGA, PCR and 
sequencing (2)
1
2
1
2
1
2
Both sequences are 
bad, then discard the 
sample
Bad sequence, then 
discard the sample
Good sequence, then 
keep the sample in 
analyses
B C
Fig. 6 Proposed strategy to test
the quality of DNA from WGA
products derived from FFPE
tissue. The original DNA is used
for additional WGA rounds
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the remaining 18 ccRCC samples. To our knowledge, there
are no studies to date demonstrating that VHL mutations are
expressed at the RNA level in sporadic ccRCC, regardless
of the mutation type.
In 7 of 20 cases, the VHLmutation could not be evaluated
after the first WTA. After repeating the WTA, the VHL
mutations were found in five cases but were not visible in
two samples. Not only technical problems (no PCR product of
the VHL fragment or non-analyzable sequence) but also VHL
mutations, which can lead to the downregulation or even to
the loss of RNA expression, may explain the discrepant find-
ings. These results demonstrate that whole transcriptomes
from frozen tissues are linearly amplified and are applicable
for gene expression, specific gene mutation, as well as RNA-
Seq analyses.
WTA of RNA extracted from FFPE tumor tissue
As already outlined for DNA, the quality of the RNA
extracted from FFPE material is similarly low and, there-
fore, of limited value for molecular analysis [24]. The am-
plification of sequences becomes increasingly problematic
with the size of the PCR product. To ensure that only cDNA
was being amplified, we worked with primer pairs that
spanned two VHL exons. The sizes of the PCR fragments
were, however, too large to amplify sufficient amounts of
DNA for sequence analysis. As it was suggested in other
studies [1, 25, 26], our results imply that a successful WTA-
based mutation analysis of FFPE tissue is strongly depen-
dent on the chosen size of the PCR fragment to be analyzed
and the age of the tissue sample.
WGA and WTA for economic tumor tissue biobanking?
WGA and WTA technologies can help to provide sufficient
amounts of high quality nucleic acids from valuable tumor
tissue material for research purposes in tumor tissue bio-
banking. By using fixed and non-fixed ccRCC nucleic acids
with known VHL mutations, we demonstrate that nucleic
acids from frozen tumor tissue are most suitable for WGA
and WTA. The severity of the modification and degradation
of nucleic acids in FFPE tumor tissue often differs and thus
hampers the accurate amplification. Additional rounds of
WGA or WTA and validation experiments lead to increased
costs. In Switzerland, one WGA costs approximately 10
Swiss Francs and one WTA is about eight times more
expensive. The routine use of WGA and WTA for large
tumor tissue biobanks, which receive thousands of tissue
samples annually, would cause an enormous financial bur-
den on a biobank’s budget, in terms of manpower, consum-
ables, freezers, space, and logistics. In contrast, research
projects usually focus on analyzing a few dozen up to
several hundred tissue samples of one specific tumor type,
which represents only a tiny part of the whole inventory of a
large tumor tissue biobank. The use ofWGA andWTA should
be restricted to those tissue samples, preferably frozen ones,
required for approved research projects. This would help to
keep the costs within an affordable limit. Furthermore, to
financially fund tumor tissue biobanks, it will be of utmost
importance for cancer research scientists to include costs for
tissue biobanking, such as sampling, storing, and processing
as well as the costs for WGA andWTA in grant applications if
they intend to work with DNA and RNA from cancer tissue.
Conclusions
Our data indicate that both WGA and WTA are feasible with
nucleic acids extracted from frozen and FFPE tissue. Never-
theless, the use of the latter has certain limitations and the
results should be interpreted with caution. Although standard-
ized procedures are required to guarantee the high quality of
frozen tissue collections, it seems that non-standardized pro-
tocols formerly used for snap freezing native tissue samples
do not negatively influence the outcome of WGA and WTA.
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